Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians

Canadian Journal of Psychiatry

Volumn 45, Issue 5, 2000, Pages 476-481

  Mischoulon, David ^a   Nierenberg, Andrew A ^a   Kizilbash, Leena ^a   Rosenbaum, Jerrold F ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Augmentation; Bupropion; Refractory depression; Selective serotonin reuptake inhibitors; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; LITHIUM; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER;

ARTICLE; COMPARATIVE STUDY; DEPRESSION; FEMALE; HUMAN; MALE; PROFESSIONAL COMPETENCE; QUESTIONNAIRE;

ANTIMANIC AGENTS; BUPROPION; DEPRESSIVE DISORDER; FEMALE; HUMANS; LITHIUM; MALE; PROFESSIONAL COMPETENCE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 0034203663     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370004500509     Document Type: Article

References (27)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
2. Fava M, Kaji K. Continuation and maintenance treatments of major depressive disorder. Psychiatric Annals 1994;24:281-90.
3. Rosenbaum JF, Fava M, Nierenberg AA, Sachs G. Treatment-resistant mood disorders. In: Gabbard GO, editor. Treatments of psychiatric disorders. Volume 1. 2nd ed. Washington (DC): American Psychiatric Press; 1995, p 1276-328.
4. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.
5. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54 Suppl:42-9. Discussion 55-6.
6. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
7. Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-1.
8. Schweitzer I, Tuckwell V, Johnson G: A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician. Aust N Z J Psychiatry 1997;31:340-52.
9. Hjorth S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. European Journal of Pharmacology 1996;303:183-6.
10. Tome MB, Cloninger CR, Watson JP, Isaac MT. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord 1997;44:101-9.
11. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
12. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin re-uptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
13. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997;87(4 Suppl):534-7, 540.
14. Sprenger D. Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence. J Clin Psychopharmacol 1997;17:425-6.
15. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21.
16. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 1996;32:175-80.
17. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
18. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-6.
19. Shergill SS, Katona CL. Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. J Affect Disord 1997;43:19-25.
20. Nierenberg AA. Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. J Clin Psychiatry 1991;53:416-7.
21. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997;48:835-7.
22. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry 1999;6:322-6.
23. American Psychiatric Association. Practice guideline for major depressive disorders in adults. Washington (DC): American Psychiatric Association Press; 1993.
24. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial of fluoxetine? J Clin Psychiatry 1990;51:8-11.
25. Rickels K, Smith WT, Glaudin V, Amsterdam JB, Weise C, Settle GP. Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry 1985;46:38-41.
26. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, Lineberry CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-65.
27. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI co-therapy. Biol Psychiatry 1998;43:99S.